14
Participants
Start Date
July 10, 2020
Primary Completion Date
August 30, 2024
Study Completion Date
August 30, 2024
Elotuzumab, pomalidomide, dexamethasone
Study Patients with relapsed Multiple Myeloma will receive: Elotuzumab, Pomalidomide, and Dexamethasone Starting in Phase 2 Cycle 1 Day 1 forward. Each cycle is 28 days long.
Anti-LAG-3
"Patients with relapsed Multiple Myeloma will receive: Anti -LAG-3 single agent for Cycle 1. Each Cycle is 28 days~Cycle 2 forward patients will receive Anti-LAG-3 in combination with pomalidomide and dexamethasone from Cycle 2 forward. Each cycle is 28 days long."
Anti-LAG-3 + Pomalidimide + Dexamethasone
Patients with Relapsed \& Refractory Multiple Myeloma will receive: Anti-LAG-3 in combination with pomalidomide and dexamethasone from Cycle 2 forward. Each cycle is 28 days.
Anti-TIGIT
"Patients with relapsed Multiple Myeloma will receive: Anti -TIGIT single agent for Cycle 1.~Each cycle is 28 days."
Anti-TIGIT + Pomalidimide + Dexamethasone
Cycle 2 and beyond patients will receive Anti-TIGIT in combination with pomalidomide and dexamethasone from Cycle 2 forward. Each cycle is 28 days..
Mount Sinai School of Medicine, New York
Memorial Sloan Kettering Cancer Center, New York
Levine Cancer Institute, Charlotte
Emory University, Atlanta
University of Michigan, Ann Arbor
Washington University School of Medicine Division of Medical Oncology, St Louis
UT Southwestern Medical Center, Dallas
Beth Israel Deaconess Medical Center, Boston
Dana Farber Cancer Institute, Boston
Hackensack Meridian Medical Center, Hackensack
Collaborators (1)
Bristol-Myers Squibb
INDUSTRY
Emory University
OTHER
Washington University School of Medicine
OTHER
Beth Israel Deaconess Medical Center
OTHER
Dana-Farber Cancer Institute
OTHER
Wake Forest University Health Sciences
OTHER
Memorial Sloan Kettering Cancer Center
OTHER
Icahn School of Medicine at Mount Sinai
OTHER
University of Texas
OTHER
Hackensack Meridian Health
OTHER
University of Michigan
OTHER
Multiple Myeloma Research Consortium
NETWORK